Cofounders Capital
SelectiveCary, NCLodging and Conventions, BiotechnologyLast fund filed 2026
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Cofounders Capital Fund IV | 2026 | Indefinite | $25M | 57 |
| Cofounders Capital Fund III | February 2022 | $50M | $24M | 53 |
| Cofounders Capital Fund II | April 2018 | $31M | $31M | 99 |
| Cofounders Capital Fund I | June 2015 | $12M | $11M | 57 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David Gardner | Selective | AI & machine learning, Biotech & pharma, E-commerce & marketplaces | 37 | 3 |
| Timothy McLoughlin | Quiet | Enterprise software | 8 | 0 |
| Tobias Walter | Quiet | E-commerce & marketplaces | 3 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Cofounders Capital’s own portfolio companies, based on 9 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Cofounders Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Atlas Venture | 1 | Xilio Therapeutics |
| Bain Capital Life Sciences | 1 | Xilio Therapeutics |
| MetaProp | 1 | Pest Share |
| SV Life Sciences | 1 | Xilio Therapeutics |
| Virtuoso-mccarran | 1 | Xilio Therapeutics |
A shared board seat: a company where filings name a Cofounders Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.